| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NF-kappa B p50 Subunit | 8 | 2020 | 38 | 3.460 |
Why?
|
| Brain Neoplasms | 15 | 2023 | 834 | 2.960 |
Why?
|
| NF-kappa B | 7 | 2021 | 417 | 2.550 |
Why?
|
| Glioma | 8 | 2019 | 307 | 2.090 |
Why?
|
| Dacarbazine | 6 | 2018 | 103 | 2.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2019 | 136 | 2.010 |
Why?
|
| Glioblastoma | 7 | 2025 | 292 | 1.910 |
Why?
|
| Hydrocephalus | 6 | 2022 | 80 | 1.320 |
Why?
|
| DNA Damage | 6 | 2019 | 397 | 1.180 |
Why?
|
| Cerebrospinal Fluid Shunts | 6 | 2022 | 32 | 1.050 |
Why?
|
| Genomic Instability | 2 | 2020 | 90 | 1.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 305 | 0.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 1372 | 0.910 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 676 | 0.770 |
Why?
|
| Cell Line, Tumor | 11 | 2025 | 2839 | 0.740 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 46 | 0.660 |
Why?
|
| Spinal Cord Compression | 2 | 2012 | 49 | 0.640 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2020 | 20 | 0.630 |
Why?
|
| Dura Mater | 2 | 2012 | 47 | 0.600 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 78 | 0.600 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 185 | 0.590 |
Why?
|
| Pituitary Neoplasms | 3 | 2025 | 74 | 0.590 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 653 | 0.590 |
Why?
|
| Cell Cycle | 1 | 2020 | 518 | 0.570 |
Why?
|
| Transcription Factors | 2 | 2018 | 1698 | 0.560 |
Why?
|
| Supratentorial Neoplasms | 1 | 2018 | 9 | 0.560 |
Why?
|
| Magnetite Nanoparticles | 1 | 2018 | 26 | 0.560 |
Why?
|
| Dog Diseases | 1 | 2018 | 36 | 0.550 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 131 | 0.530 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 137 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 551 | 0.480 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 196 | 0.470 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 456 | 0.470 |
Why?
|
| Animals | 22 | 2024 | 28471 | 0.460 |
Why?
|
| Mice | 13 | 2024 | 12495 | 0.450 |
Why?
|
| Nanoparticles | 2 | 2018 | 209 | 0.450 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2015 | 4 | 0.450 |
Why?
|
| Humans | 48 | 2026 | 96382 | 0.450 |
Why?
|
| Binding Sites | 4 | 2021 | 1145 | 0.440 |
Why?
|
| Aging, Premature | 1 | 2014 | 6 | 0.440 |
Why?
|
| S Phase | 1 | 2015 | 64 | 0.430 |
Why?
|
| Promoter Regions, Genetic | 6 | 2021 | 974 | 0.430 |
Why?
|
| DNA Replication | 1 | 2015 | 169 | 0.410 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 70 | 0.410 |
Why?
|
| Transcription Factor RelA | 2 | 2018 | 39 | 0.400 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 355 | 0.400 |
Why?
|
| Brain | 6 | 2022 | 2415 | 0.390 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2025 | 62 | 0.390 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2007 | 706 | 0.380 |
Why?
|
| Hydrodynamics | 1 | 2022 | 21 | 0.380 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2012 | 23 | 0.370 |
Why?
|
| Mice, Nude | 4 | 2019 | 829 | 0.330 |
Why?
|
| Adenoma | 2 | 2025 | 260 | 0.320 |
Why?
|
| Signal Transduction | 2 | 2024 | 3563 | 0.320 |
Why?
|
| Endoscopy | 3 | 2004 | 378 | 0.310 |
Why?
|
| Convection | 3 | 2018 | 11 | 0.310 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 2348 | 0.310 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1768 | 0.300 |
Why?
|
| Aging | 1 | 2014 | 757 | 0.300 |
Why?
|
| DNA Methylation | 2 | 2023 | 713 | 0.290 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2008 | 73 | 0.280 |
Why?
|
| Genetic Therapy | 4 | 2019 | 371 | 0.280 |
Why?
|
| Eyebrows | 1 | 2008 | 10 | 0.270 |
Why?
|
| Epidural Abscess | 1 | 2008 | 6 | 0.270 |
Why?
|
| Sacrum | 1 | 2008 | 81 | 0.270 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2007 | 18 | 0.270 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2007 | 25 | 0.270 |
Why?
|
| Orbit | 1 | 2008 | 38 | 0.270 |
Why?
|
| Alkylation | 2 | 2020 | 31 | 0.260 |
Why?
|
| Phosphorylation | 3 | 2015 | 1140 | 0.260 |
Why?
|
| Spinal Neoplasms | 1 | 2008 | 127 | 0.260 |
Why?
|
| Craniotomy | 1 | 2008 | 99 | 0.260 |
Why?
|
| Adenoviridae | 2 | 2007 | 340 | 0.260 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 155 | 0.250 |
Why?
|
| Male | 19 | 2026 | 46116 | 0.250 |
Why?
|
| Serine | 2 | 2020 | 104 | 0.250 |
Why?
|
| Wilms Tumor | 1 | 2006 | 30 | 0.240 |
Why?
|
| Guanine | 1 | 2007 | 194 | 0.240 |
Why?
|
| Craniopharyngioma | 1 | 2006 | 13 | 0.240 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3221 | 0.240 |
Why?
|
| Cisterna Magna | 2 | 2022 | 7 | 0.240 |
Why?
|
| Intracranial Pressure | 2 | 2022 | 75 | 0.230 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2006 | 78 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 3527 | 0.220 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 285 | 0.220 |
Why?
|
| Ventriculostomy | 2 | 2004 | 25 | 0.220 |
Why?
|
| Base Sequence | 2 | 2021 | 2219 | 0.220 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 373 | 0.220 |
Why?
|
| Fibroblasts | 2 | 2020 | 759 | 0.220 |
Why?
|
| Polymers | 2 | 2018 | 221 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 3562 | 0.210 |
Why?
|
| STAT1 Transcription Factor | 1 | 2024 | 59 | 0.210 |
Why?
|
| Pinealoma | 1 | 2004 | 6 | 0.210 |
Why?
|
| Drug Design | 1 | 2025 | 135 | 0.210 |
Why?
|
| Pineal Gland | 1 | 2004 | 16 | 0.210 |
Why?
|
| Proteolysis | 1 | 2025 | 126 | 0.210 |
Why?
|
| Sella Turcica | 2 | 2019 | 18 | 0.210 |
Why?
|
| Protein Binding | 3 | 2015 | 1540 | 0.200 |
Why?
|
| Cellular Senescence | 2 | 2015 | 108 | 0.200 |
Why?
|
| Intracranial Aneurysm | 1 | 2026 | 239 | 0.200 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2024 | 82 | 0.200 |
Why?
|
| Neurosurgery | 1 | 2005 | 144 | 0.200 |
Why?
|
| Animals, Newborn | 1 | 2024 | 521 | 0.190 |
Why?
|
| Neurosurgical Procedures | 3 | 2022 | 396 | 0.190 |
Why?
|
| Mice, Knockout | 3 | 2024 | 2164 | 0.190 |
Why?
|
| Female | 16 | 2026 | 50528 | 0.190 |
Why?
|
| Cell Death | 2 | 2014 | 254 | 0.180 |
Why?
|
| Otolaryngology | 1 | 2022 | 59 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 120 | 0.170 |
Why?
|
| Luciferases | 2 | 2015 | 128 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 509 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2021 | 9526 | 0.170 |
Why?
|
| Time Factors | 7 | 2021 | 5524 | 0.170 |
Why?
|
| Intracranial Thrombosis | 1 | 2001 | 31 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 515 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 551 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2018 | 1525 | 0.160 |
Why?
|
| Ubiquitination | 1 | 2020 | 78 | 0.160 |
Why?
|
| DNA Probes | 1 | 2020 | 66 | 0.160 |
Why?
|
| Protein Domains | 1 | 2020 | 163 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2020 | 67 | 0.150 |
Why?
|
| Prognosis | 3 | 2025 | 4041 | 0.150 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2001 | 158 | 0.150 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 829 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 528 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2001 | 180 | 0.150 |
Why?
|
| Cerebral Ventricles | 1 | 1999 | 66 | 0.150 |
Why?
|
| Transcription, Genetic | 3 | 2012 | 1124 | 0.150 |
Why?
|
| Lysine | 1 | 2020 | 181 | 0.150 |
Why?
|
| Radiography | 2 | 2013 | 756 | 0.150 |
Why?
|
| Optic Chiasm | 1 | 2019 | 17 | 0.150 |
Why?
|
| Fibrinolytic Agents | 1 | 2001 | 242 | 0.150 |
Why?
|
| Paraganglioma | 1 | 2019 | 15 | 0.140 |
Why?
|
| Interleukin-12 | 1 | 2019 | 109 | 0.140 |
Why?
|
| DNA | 3 | 2014 | 1270 | 0.140 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 258 | 0.140 |
Why?
|
| Carbonic Anhydrase II | 1 | 2018 | 4 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 255 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2018 | 85 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 238 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 97 | 0.140 |
Why?
|
| Cerebral Hemorrhage | 1 | 2021 | 368 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 406 | 0.130 |
Why?
|
| Vasospasm, Intracranial | 4 | 2001 | 38 | 0.130 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 108 | 0.130 |
Why?
|
| Cerebral Angiography | 6 | 2026 | 263 | 0.130 |
Why?
|
| Dogs | 1 | 2018 | 636 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 167 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 2600 | 0.130 |
Why?
|
| Protein Multimerization | 1 | 2018 | 191 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 631 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2018 | 332 | 0.130 |
Why?
|
| Neuroblastoma | 1 | 2020 | 404 | 0.120 |
Why?
|
| Child | 6 | 2022 | 7540 | 0.120 |
Why?
|
| Radiation, Ionizing | 2 | 2014 | 123 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 906 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1007 | 0.120 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 10c | 1 | 2015 | 3 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 962 | 0.110 |
Why?
|
| GPI-Linked Proteins | 1 | 2015 | 57 | 0.110 |
Why?
|
| Comet Assay | 1 | 2015 | 8 | 0.110 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2015 | 74 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 370 | 0.110 |
Why?
|
| Gliosis | 1 | 2014 | 32 | 0.110 |
Why?
|
| Middle Aged | 6 | 2025 | 28794 | 0.110 |
Why?
|
| Kyphosis | 1 | 2014 | 24 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 136 | 0.110 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 64 | 0.110 |
Why?
|
| Rats | 2 | 2013 | 4051 | 0.110 |
Why?
|
| Immunoblotting | 1 | 2015 | 273 | 0.110 |
Why?
|
| Longevity | 1 | 2014 | 63 | 0.100 |
Why?
|
| Apoptosis | 2 | 2014 | 1731 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2007 | 1738 | 0.100 |
Why?
|
| DNA Primers | 1 | 2015 | 530 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 293 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 301 | 0.100 |
Why?
|
| RNA Interference | 1 | 2015 | 381 | 0.100 |
Why?
|
| Pseudotumor Cerebri | 2 | 2004 | 14 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2014 | 268 | 0.100 |
Why?
|
| Heterozygote | 1 | 2014 | 386 | 0.100 |
Why?
|
| Ferric Compounds | 1 | 2013 | 41 | 0.100 |
Why?
|
| Adult | 9 | 2025 | 28968 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 888 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 2640 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2014 | 527 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1026 | 0.090 |
Why?
|
| Nucleotides | 1 | 2012 | 93 | 0.090 |
Why?
|
| Equipment Failure | 3 | 2022 | 119 | 0.090 |
Why?
|
| Histones | 1 | 2014 | 364 | 0.090 |
Why?
|
| Aged | 7 | 2026 | 21309 | 0.090 |
Why?
|
| Skull Base | 2 | 2022 | 54 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1633 | 0.090 |
Why?
|
| Gene Expression | 1 | 2015 | 1313 | 0.080 |
Why?
|
| Brain Diseases | 2 | 2004 | 175 | 0.080 |
Why?
|
| Hematoma | 2 | 2001 | 106 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 1879 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1957 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2845 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2014 | 2041 | 0.070 |
Why?
|
| Infant | 4 | 2007 | 3259 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2025 | 1069 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2026 | 10719 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 2005 | 0.070 |
Why?
|
| Cell Line | 1 | 2012 | 2478 | 0.070 |
Why?
|
| Inflammation | 1 | 2014 | 1100 | 0.070 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2008 | 5 | 0.070 |
Why?
|
| Pneumocephalus | 1 | 2008 | 12 | 0.070 |
Why?
|
| Frontal Sinus | 1 | 2008 | 7 | 0.070 |
Why?
|
| Phenotype | 1 | 2014 | 2602 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 84 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 122 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 79 | 0.060 |
Why?
|
| Parietal Bone | 1 | 2007 | 16 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2007 | 380 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 399 | 0.060 |
Why?
|
| Drainage | 1 | 2008 | 174 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2004 | 3905 | 0.060 |
Why?
|
| Craniosynostoses | 1 | 2007 | 76 | 0.060 |
Why?
|
| Frontal Lobe | 1 | 2006 | 128 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 435 | 0.060 |
Why?
|
| Fracture Fixation, Internal | 1 | 2007 | 91 | 0.060 |
Why?
|
| Aneurysm, Ruptured | 1 | 2026 | 80 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 34 | 0.060 |
Why?
|
| Parietal Lobe | 1 | 2006 | 115 | 0.060 |
Why?
|
| Sinusitis | 1 | 2008 | 215 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 317 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 1118 | 0.060 |
Why?
|
| Hospitals, High-Volume | 1 | 2025 | 46 | 0.060 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 41 | 0.050 |
Why?
|
| Monitoring, Ambulatory | 1 | 2004 | 32 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2025 | 109 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2026 | 182 | 0.050 |
Why?
|
| Telemetry | 1 | 2004 | 30 | 0.050 |
Why?
|
| Central Nervous System Cysts | 1 | 2004 | 11 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2025 | 425 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 3969 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2026 | 281 | 0.050 |
Why?
|
| Cerebral Arteries | 2 | 2001 | 74 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1934 | 0.050 |
Why?
|
| Stroke | 1 | 2022 | 1140 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 652 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 2528 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 400 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 1235 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 106 | 0.050 |
Why?
|
| Cell Survival | 1 | 2004 | 1012 | 0.040 |
Why?
|
| Office Visits | 1 | 2021 | 48 | 0.040 |
Why?
|
| Membranes, Artificial | 1 | 2001 | 39 | 0.040 |
Why?
|
| Macaca fascicularis | 4 | 2001 | 111 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 165 | 0.040 |
Why?
|
| Adolescent | 3 | 2004 | 9948 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 411 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 705 | 0.040 |
Why?
|
| Ferritins | 1 | 2000 | 28 | 0.040 |
Why?
|
| Biopsy | 1 | 2004 | 1196 | 0.040 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2000 | 46 | 0.040 |
Why?
|
| Neoplasms | 2 | 2006 | 3271 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2528 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cysts | 1 | 1999 | 100 | 0.040 |
Why?
|
| Thrombosis | 1 | 2001 | 315 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7277 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 461 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2001 | 340 | 0.030 |
Why?
|
| Disease Progression | 2 | 2018 | 1586 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2019 | 314 | 0.030 |
Why?
|
| Quality of Life | 1 | 2006 | 1869 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 301 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2019 | 470 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 899 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1759 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 430 | 0.030 |
Why?
|
| Reoperation | 1 | 1999 | 715 | 0.030 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2006 | 58 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 639 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1549 | 0.030 |
Why?
|
| United States | 1 | 2025 | 7976 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1504 | 0.020 |
Why?
|
| Mutation | 1 | 2023 | 4325 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1999 | 4742 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2001 | 194 | 0.020 |
Why?
|
| Bone Wires | 1 | 2007 | 11 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2005 | 7 | 0.010 |
Why?
|
| Tumor Necrosis Factors | 1 | 2005 | 14 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 426 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 554 | 0.010 |
Why?
|
| Length of Stay | 1 | 2007 | 860 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2002 | 19 | 0.010 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2002 | 21 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2002 | 57 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 2001 | 17 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2001 | 45 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 2001 | 75 | 0.010 |
Why?
|
| Basilar Artery | 1 | 2001 | 42 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2001 | 24 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2001 | 88 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 437 | 0.010 |
Why?
|
| Vascular Patency | 1 | 2001 | 122 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 280 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2000 | 23 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 287 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2001 | 945 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 889 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1792 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 2481 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 2647 | 0.010 |
Why?
|